厄洛替尼一线治疗老年非小细胞肺癌脑转移7例疗效观察  

Erlotinib as the first-line therapy in elderly patients with brain metastasis from non-small cell lung cancer

作　　者：江再茂[1] 丁江华[1] 左新年[1] 

机构地区：[1]中国人民解放军第171医院,江西九江332000

出　　处：《安徽医药》2012年第6期824-825,共2页Anhui Medical and Pharmaceutical Journal

摘　　要：目的探讨厄洛替尼一线治疗老年非小细胞肺癌(NSCLC)脑转移的疗效与安全性。方法对7例确诊的老年非小细胞肺癌患者,应用厄洛替尼150 mg·d-1,直到病情进展。结果厄洛替尼治疗老年非小细胞肺癌脑转移的ORR为57.1%,DCR为85.7%,中位OS为12月,1年生存率为42.9%,2年生存率为28.6%。结论厄洛替尼一线治疗老年NSCLC脑转移,具有较好的临床疗效,毒副反应轻,可耐受。Objective To explore the efficacy and safety of erlotinib as the first-line therapy on brain metastasis in elderly patients with non-small cell lung caners （NSCLC）. Methods 7 elderly patients with brain metastasis from advanced NSCLC were treated with erlotin- ib of 150 mg · d^-1 as the first-line therapy and they would discontinue erlotinib for disease progression. Results The overall response rate and disease control rate of erlotinib for brain metastasis from NSCLC were 57.1% and 85.7%. The media overall survival is 12 months. The rates of 1 year and 2 year survival were 42.9% and 28.6% respectively. Conclusions Erlotinib as the first-line therapy in the NSCLC patients with brain metastasis have satisfactory curative effects with a better drug tolerance.

关 键 词：非小细胞肺癌 脑转移 厄洛替尼一线治疗 老年 

分 类 号：R734.2[医药卫生—肿瘤]